Ihr Broker

  • Sonderkonditionen
  • Mehrfach reguliert
  • Sehr finanzstark
  • Reguliert in CYPERN & Australien

Mehr Erfahren >>

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

trading-house Börsenakademie

Gemeinsam erfolgreich

MARKETS.COM
Heidelberg Pharma AG, DE000A11QVV0

Heidelberg Pharma AG, DE000A11QVV0

11.06.2019 - 07:21:15

Heidelberg Pharma AG Presents Proprietary ATAC Technology Platform at Two Scientific Conferences

PRESS RELEASE

Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences

Ladenburg, Germany, 11 June 2019 - Heidelberg Pharma AG (FWB: WL6) today announced that they will present their proprietary technology for Antibody Targeted Amanitin Conjugates as potential therapeutic modality for cancer therapy at two upcoming scientific conferences.

2nd World ADC Asia Conference Date: 11 - 13 June 2019 Venue: Wyndham Grand Plaza Royale Oriental, Shanghai, China

Dr. George Badescu, Vice President Scientific Affairs, will present on Wednesday, 12 June 2019 at 14:30 CST.

Information on the conference: https://worldadc-asia.com/

Next Generation Protein Therapeutics & Bioconjugates Summit Date: 18 June 2019 Venue: Park Central Hotel, San Francisco, CA, USA

Dr. George Badescu, Vice President Scientific Affairs, will present on Tuesday, 18 June 2019 at 11:00 PDT.

Information on the conference: https://get.knect365.com/next-gen-protein/brochure/

About Heidelberg Pharma's proprietary ATAC technology Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

Contact Heidelberg Pharma AG Corporate Communications Sylvia Wimmer Tel.: +49 89 41 31 38-29 E-Mail: investors[at]hdpharma.com Schriesheimer Str. 101, 68526 Ladenburg IR/PR support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89 210 228-40 Mobil: +49 160 9360 3022 E-Mail: katja.arnold[at]mc-services.eu  

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

11.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Heidelberg Pharma AG Schriesheimer Str. 101 68526 Ladenburg

Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: investors@hdpharma.com Internet: www.heidelberg-pharma.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange EQS News ID: 822219   End of News DGAP News Service

822219  11.06.2019 

@ dgap.de